PDF Print E-mail

Updated Information on Approved Treatments

This section of the website contains important updates concerning FDA-approved MS treatments. For those medications that were approved prior to the creation of the Emerging Therapies site, the updates will be posted here. Updates to existing information sheets and for people affected by MS will be added to the documents themselves as well as posted here.

HTML-based document / Adobe PDF document

  • Dalfampridine (Ampyra)
    • July 26, 2012
      Information for clinicians HTML
      Information for people affected by MS HTML
  • Dimethyl Fumarate (Tecfidera)
    • December 2014
      Information for clinicians
  • Fingolimod (Gilenya)
    • April 17, 2012
      Information for clinicians and for people affected by MS
    • February 10, 2012
      Information for clinicians and for people affected by MS
  • Glatiramer Acetate (Copaxone)
    • February 10, 2014
      Information for clinicians HTML
      Information for people affected by MS HTML
  • Natalizumab (Tysabri)
    • January 2014
      Information for clinicians HTML
      Information for people affected by MS HTML
    • August 24, 2012
      Information for clinicians HTML
      Information for people affected by MS HTML
    • July 24, 2012
      Information for clinicians HTML
      Information for people affected by MS HTML
    • February 10, 2012
      Information for clinicians
      Information for people affected by MS
  • Teriflunomide (Aubagio)
    • November 21, 2014
      Information for clinicians
    • December 3, 2014
      Information for patients


DISCLAIMER:
The Emerging Therapies Collaborative is proud to be a source of information about multiple sclerosis. Our comments are based on published data and expert opinion, but do not represent individual therapeutic recommendations or prescriptions. For specific information and advice, consult your physician.

Last Updated on Friday, 12 December 2014 13:38